back to US directory
us clinical guidance

Familial hypercholesterolemia

US recognition, family assessment, early LDL lowering and specialist escalation for suspected or confirmed familial hypercholesterolemia.

JurisdictionUnited States
Source check2026-08-20
Clinical reviewiatroX editorial team 路 Clinical editorial review 路 reviewed 2026-08-20 路 due 2027-08-20
AudienceUnited States healthcare professionals
This is an iatroX educational summary of named United States sources, not an official guideline. It does not replace the complete source documents, local policy, specialist advice or clinical judgement. Use the named authority, current FDA labeling, applicable state law, payer rules and local protocol where relevant.

Scope of this summary

Children and adults with markedly elevated LDL cholesterol, a family history of high cholesterol or premature atherosclerotic cardiovascular disease, or a prior clinical or genetic diagnosis of familial hypercholesterolemia (FH).
sources for this section:ACC/AHA lipids 2026

The Bottom Line

  • Recognize FH early because lifelong exposure to high LDL cholesterol drives premature atherosclerotic disease; the 2026 guideline supports early lifestyle treatment and early consideration of pharmacotherapy in youth with FH.
  • Review untreated lipid values, premature ASCVD in the patient and family, physical findings, secondary causes and prior treatment response rather than interpreting one on-treatment result in isolation.
  • Once FH is suspected, evaluate close relatives through a structured family or cascade approach and consider lipid-specialist and genetic-counseling input where testing will clarify care.
  • Use maximally tolerated statin-based LDL lowering and intensify with evidence-based nonstatins when the guideline-defined response or goal is not achieved.
  • Assess the full burden of risk, including lipoprotein(a), smoking, hypertension, diabetes and established ASCVD, and address reproductive and adherence issues over a lifetime.
sources for this section:ACC/AHA lipids 2026

Practical clinical workflow

1
Recover the highest reliable untreated LDL-C and a three-generation history of premature coronary or vascular events and known severe hypercholesterolemia.
2
Repeat a lipid profile when needed, evaluate secondary causes, document physical findings and calculate neither short-term PREVENT risk nor age alone as a reason to dismiss possible FH.
3
Apply the current ACC/AHA diagnostic and treatment framework; refer for specialist or genetic assessment when phenotype is severe, diagnosis uncertain or treatment response inadequate.
4
Start age-appropriate lifestyle and pharmacologic treatment, set an explicit LDL-C goal and percentage reduction, and remeasure response after changes.
5
Offer a plan for evaluating first-degree relatives and transition pediatric patients into continuous adult lipid care.
sources for this section:ACC/AHA lipids 2026

Safety boundaries and escalation

  • New chest pain, neurologic deficit or limb ischemia may represent premature ASCVD and needs acute evaluation rather than routine lipid follow-up.
  • Verify age, pregnancy and breastfeeding considerations and current FDA labeling before each lipid-lowering medicine.
  • Do not label treatment failure until adherence, access, intolerance, secondary causes and the actual achieved LDL response have been assessed.
  • Extremely high triglycerides or a mixed phenotype may require a separate pancreatitis-risk and inherited-lipid evaluation.
sources for this section:ACC/AHA lipids 2026

Localization

Use the 2026 ACC/AHA dyslipidemia framework, US pediatric/adult specialty access and current FDA labels. Insurer rules must be navigated without presenting them as clinical evidence.
sources for this section:ACC/AHA lipids 2026

Source documents

Use the linked source documents for complete recommendations, evidence grading, exclusions and implementation detail.

  1. American College of Cardiology and American Heart Association Joint Committee on Clinical Practice Guidelines2026 Guideline on the Management of DyslipidemiaDOI 10.1161/CIR.0000000000001423 路 published 2026-03-13 路 accessed 2026-08-20
    view source
continue the learning

From guidance to deliberate practice and evidence

Choose what happens next. iatroX can carry this page's jurisdiction, source-check date and released version into an editable learning record, support your reflection, or let you browse the regional question bank while keeping this topic visible. No action records completion, starts a session or awards CPD/CME credit automatically.

Add this guidance review to CPD/CMEOpen an editable learning-log record with this page鈥檚 provenance attached. You confirm the activity, time, reflection and mappings.Reflect on this with TutorUse optional prompts to consider what you learned and what鈥攊f anything鈥攜ou may change. Suggestions are never inserted automatically.Browse the US question bankKeep this guidance topic in view, then choose your exam and filters. No session starts automatically.
Found a source update or regional discrepancy? Tell the iatroX editorial team.